医学
嵌合抗原受体
耐火材料(行星科学)
药理学
肺癌
受体
配体(生物化学)
细胞
癌症研究
癌症
免疫疗法
肿瘤科
内科学
化学
生物
生物化学
天体生物学
作者
Di Zhou,Lauren A. Byers,Beate Sable,Marie‐Anne Damiette Smit,Nooshin Hashemi Sadraei,Sandeep Dutta,Vijay Upreti
摘要
Abstract With the promise of a potentially single‐dose curative regimen, CAR‐T cell therapies have brought a paradigm shift in the treatment and management of hematological malignancies with 6 approved products in the USA. However, there are no approved CAR‐T cell therapies for solid tumors. Herein, we report the clinical pharmacology profile of AMG 119, the first CAR‐T cell therapy targeting delta‐like ligand 3 (DLL3), in patients with relapsed/refractory (R/R) small cell lung cancer (SCLC). AMG 119 demonstrated robust cellular expansion with long‐lasting cell persistence and a favorable exposure–response relationship. AMG 119 has been demonstrated to be clinically safe and well tolerated at the doses tested, with no dose‐limiting toxicities (DLTs) reported. This is the first publication of the clinical pharmacology profile of a CAR‐T cell therapy in SCLC, with encouraging cellular kinetics data supporting the potential for CAR‐T cell therapy in solid tumor space.
科研通智能强力驱动
Strongly Powered by AbleSci AI